Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.
Símbolo de cotizaciónRGNT
Nombre de la empresaRegentis Biomaterials Ltd
Fecha de salida a bolsaDec 04, 2025
Director ejecutivoHazum (Eli)
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscal- -
Dirección60, Medinat Hyahudim
CiudadHERZLIYA
Bolsa de valoresNASDAQ OMX – NASDAQ Basic Amex
PaísIsrael
Código postal4676652
Teléfono97246265502
Sitio Webhttps://www.regentis.co.il/
Símbolo de cotizaciónRGNT
Fecha de salida a bolsaDec 04, 2025
Director ejecutivoHazum (Eli)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos